• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[系统性红斑狼疮治疗中已得到证实的是什么?]

[What is proven in the treatment of systemic lupus erythematosus?].

作者信息

Gödecke Vega, Witte Torsten

机构信息

Klinik für Nieren- und Hochdruckerkrankungen, Medizinische Hochschule Hannover, Carl-Neuberg-Straße 1, 30625, Hannover, Deutschland.

Klinik für Rheumatologie und Immunologie, Medizinische Hochschule Hannover, Carl-Neuberg-Straße 1, 30625, Hannover, Deutschland.

出版信息

Z Rheumatol. 2024 Aug;83(6):439-446. doi: 10.1007/s00393-024-01551-6.

DOI:10.1007/s00393-024-01551-6
PMID:39037548
Abstract

Systemic lupus erythematosus (SLE) is an autoimmune disease with variable clinical presentation and organ involvement. Early diagnosis and rapid achievement of low disease activity or remission reduces organ damage and improves prognosis. Therapeutic principles can be divided into so-called basic measures and immunosuppressive treatment. Novel drugs have been developed in recent years, with new classes of agents being added for the treatment of SLE. These include biologic therapies and approved therapeutic options for the treatment of lupus nephritis. In light of improved treatment options, good disease control can now frequently be achieved; with savings on glucocorticoids, combination therapies are increasingly being used. Of great importance is the consistent use of basic measures, which include the use of hydroxychloroquine, optimization of cardiovascular risk factors, UV protection, bone-protective measures, and the implementation of vaccinations. In the treatment of lupus nephritis, conservative therapeutic measures for nephroprotection play a crucial role in renal prognosis. Finally, non-pharmacological therapy options such as exercise therapy are of great importance for improving quality of life.

摘要

系统性红斑狼疮(SLE)是一种临床表现多样且累及多器官的自身免疫性疾病。早期诊断并迅速实现低疾病活动度或缓解可减少器官损害并改善预后。治疗原则可分为所谓的基本措施和免疫抑制治疗。近年来已研发出新型药物,治疗SLE的新型药物类别不断增加。这些药物包括生物疗法以及获批用于治疗狼疮性肾炎的治疗方案。鉴于治疗选择的改善,目前常常能够实现良好的疾病控制;随着糖皮质激素用量的减少,联合疗法的应用越来越广泛。持续采用基本措施非常重要,这些措施包括使用羟氯喹、优化心血管危险因素、紫外线防护、骨骼保护措施以及接种疫苗。在狼疮性肾炎的治疗中,肾脏保护的保守治疗措施对肾脏预后起着至关重要的作用。最后,运动疗法等非药物治疗选择对于提高生活质量非常重要。

相似文献

1
[What is proven in the treatment of systemic lupus erythematosus?].[系统性红斑狼疮治疗中已得到证实的是什么?]
Z Rheumatol. 2024 Aug;83(6):439-446. doi: 10.1007/s00393-024-01551-6.
2
[What is proven in the treatment of systemic lupus erythematosus?].[系统性红斑狼疮治疗中已得到证实的是什么?]
Inn Med (Heidelb). 2023 Dec;64(12):1135-1142. doi: 10.1007/s00108-023-01624-9. Epub 2023 Nov 7.
3
Update οn the diagnosis and management of systemic lupus erythematosus.红斑狼疮诊断与治疗的最新进展。
Ann Rheum Dis. 2021 Jan;80(1):14-25. doi: 10.1136/annrheumdis-2020-218272. Epub 2020 Oct 13.
4
[EULAR recommendations 2023 on the treatment of systemic lupus erythematosus -Implications for treatment in Germany].[2023年欧洲抗风湿病联盟关于系统性红斑狼疮治疗的建议——对德国治疗的启示]
Z Rheumatol. 2024 Aug;83(6):431-438. doi: 10.1007/s00393-024-01544-5. Epub 2024 Jul 22.
5
Glucocorticoid, immunosuppressant, hydroxychloroquine monotherapy, or no therapy for maintenance treatment in systemic lupus erythematosus without major organ manifestations.无重要器官表现的系统性红斑狼疮维持治疗中,糖皮质激素、免疫抑制剂、羟氯喹单药治疗或无治疗。
Clin Rheumatol. 2019 Oct;38(10):2785-2791. doi: 10.1007/s10067-019-04633-y. Epub 2019 Jun 7.
6
[Treatment of systemic lupus erythematosus: myths, certainties and doubts].[系统性红斑狼疮的治疗:误区、定论与疑问]
Med Clin (Barc). 2013 Dec 21;141(12):533-42. doi: 10.1016/j.medcli.2013.02.014. Epub 2013 Apr 23.
7
An Update on the Management of Childhood-Onset Systemic Lupus Erythematosus.儿童发病系统性红斑狼疮的治疗进展。
Paediatr Drugs. 2021 Jul;23(4):331-347. doi: 10.1007/s40272-021-00457-z. Epub 2021 Jul 10.
8
Prevalence of remission and its effect on damage and quality of life in Chinese patients with systemic lupus erythematosus.中国系统性红斑狼疮患者缓解的流行率及其对损害和生活质量的影响。
Ann Rheum Dis. 2017 Aug;76(8):1420-1425. doi: 10.1136/annrheumdis-2016-210382. Epub 2017 Apr 21.
9
[Management of systemic lupus erythematosus].[系统性红斑狼疮的管理]
Internist (Berl). 2016 Nov;57(11):1052-1059. doi: 10.1007/s00108-016-0135-6.
10
Balancing risks and benefits in the use of hydroxychloroquine and glucocorticoids in systemic lupus erythematosus.系统性红斑狼疮中使用羟氯喹和糖皮质激素时风险与获益的权衡
Expert Rev Clin Immunol. 2024 Apr;20(4):359-373. doi: 10.1080/1744666X.2023.2294938. Epub 2023 Dec 25.

本文引用的文献

1
Safety and Efficacy of Long-Term Voclosporin Treatment for Lupus Nephritis in the Phase 3 AURORA 2 Clinical Trial.在 3 期 AURORA 2 临床试验中,长期用 voclosporin 治疗狼疮肾炎的安全性和疗效。
Arthritis Rheumatol. 2024 Jan;76(1):59-67. doi: 10.1002/art.42657. Epub 2023 Sep 15.
2
Variations of C3 and C4 Before and During Pregnancy in Systemic Lupus Erythematosus: Association With Disease Flares and Obstetric Outcomes.系统性红斑狼疮患者妊娠前后 C3 和 C4 的变化:与疾病发作和产科结局的关系。
J Rheumatol. 2023 Oct;50(10):1296-1301. doi: 10.3899/jrheum.2022-1135. Epub 2023 May 1.
3
Annals of the Rheumatic Diseases collection on lupus nephritis (2019-2022): novel insights and advances in therapy.
《风湿病年鉴》狼疮肾炎专辑(2019-2022):治疗方面的新见解和进展。
Ann Rheum Dis. 2023 Jun;82(6):729-733. doi: 10.1136/ard-2023-223880. Epub 2023 Apr 24.
4
A Randomized, Placebo-Controlled Phase III Extension Trial of the Long-Term Safety and Tolerability of Anifrolumab in Active Systemic Lupus Erythematosus.一项评估阿尼鲁单抗在活跃系统性红斑狼疮患者中长期安全性和耐受性的随机、安慰剂对照 III 期扩展试验。
Arthritis Rheumatol. 2023 Feb;75(2):253-265. doi: 10.1002/art.42392. Epub 2022 Nov 11.
5
2021 DORIS definition of remission in SLE: final recommendations from an international task force.2021 年 DORIS 系统性红斑狼疮缓解定义:国际工作组的最终建议。
Lupus Sci Med. 2021 Nov;8(1). doi: 10.1136/lupus-2021-000538.
6
Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.与安慰剂相比,voclosporin治疗狼疮性肾炎的疗效和安全性(AURORA 1):一项双盲、随机、多中心、安慰剂对照的3期试验。
Lancet. 2021 May 29;397(10289):2070-2080. doi: 10.1016/S0140-6736(21)00578-X. Epub 2021 May 7.
7
Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis.两年随机对照试验研究贝利尤单抗治疗狼疮肾炎。
N Engl J Med. 2020 Sep 17;383(12):1117-1128. doi: 10.1056/NEJMoa2001180.
8
Lupus nephritis.狼疮性肾炎。
Nat Rev Dis Primers. 2020 Jan 23;6(1):7. doi: 10.1038/s41572-019-0141-9.
9
Trial of Anifrolumab in Active Systemic Lupus Erythematosus.阿尼鲁单抗治疗活动性系统性红斑狼疮的试验。
N Engl J Med. 2020 Jan 16;382(3):211-221. doi: 10.1056/NEJMoa1912196. Epub 2019 Dec 18.
10
Impact of tobacco smoking upon disease risk, activity and therapeutic response in systemic lupus erythematosus: A systematic review and meta-analysis.烟草使用对系统性红斑狼疮疾病风险、活动和治疗反应的影响:系统评价和荟萃分析。
Autoimmun Rev. 2019 Nov;18(11):102393. doi: 10.1016/j.autrev.2019.102393. Epub 2019 Sep 11.